Clinical trials: Lobular Breast Carcinoma in Situ
Breast Cancer
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
RATIONALE: The evaluation of breast cancer recurrence rates may improve the ability to plan cancer treatment for patients with breast cancer.
- Trial name
- NCT00002934
- Testing
- long-term screening
- Where
- 30 sites in United States, South Africa
- Volunteers
- 711 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Placing gold markers in the area where the tumor was removed may help doctors better direct radiation therapy and help reduce the risk of cancer…
- Trial name
- NCT00749437
- Testing
- 3-dimensional conformal accelerated partial breast irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Breast Ductal Carcinoma In Situ, COVID-19 Infection
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery.
- Conditions
- Breast Ductal Carcinoma In Situ, COVID-19 Infection, Hereditary Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT04169542
- Testing
- Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- M.D. Anderson Cancer Center
BRCA Mutation, PALB2 Gene Mutation
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion
Circulating levels of Sex Hormone Binding Globulin (SHBG) are significantly associated with a decreased risk of breast cancer. The main aim of this clinical trial is to verify whether Low Dose Tamoxifen (LDT) increases…
- Conditions
- BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
- Trial name
- TOLERANT (NCT06033092)
- Testing
- Tamoxifen 10 mg Tablet, Intermittent caloric restriction, Step counter Device
- Where
- 4 sites in Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Ductal Carcinoma in Situ
A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ
The investigators hypothesize that black cohosh, as a potentially therapeutic agent, will reduce the overall size and aggressiveness of ductal carcinoma in situ (DCIS) when given in a pre-operative setting.
- Trial name
- NCT01628536
- Testing
- Black cohosh
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Yale University
Ductal Carcinoma In Situ
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Primary Objectives: To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) To evaluate the effect of a single dose of Herceptin…
- Trial name
- NCT00496808
- Testing
- Herceptin (Trastuzumab)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ
- Trial name
- NCT06184750
- Testing
- Biopsy Procedure, Biospecimen Collection, Mammography
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Carcinoma in Situ
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
This will be a proof of principle clinical trial to evaluate the use of pasireotide (SOM230) in women with ductal carcinoma in situ (DCIS) of the breast.
- Trial name
- NCT01372618
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Breast Cancer
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898508
- Testing
- gene expression analysis, mutation analysis, proteomic profiling
- Where
- 3 sites in United States
- Volunteers
- 563 people
- Sponsor
- City of Hope Medical Center